Some equations used to calculate estimated glomerular filtration rate (eGFR) may alter chemotherapy dosing in cancer patients ...

Amid an 18 percent increase in cancer drug sales, J&J executives shared hopes that recent overall survival data for the drug combo will be practice changing.

The commonly used Cockcroft-Gault method may result in excessive chemotherapy dosing — with potentially dire implications.

Expert Rev Mol Diagn. 2008;8(4):417-434. Interestingly, cancers that co-overexpress EGFR and HER2 have a worse clinical outcome than those overexpressing either receptor alone. There is therefore ...

Among 117 patients with EGFR-mutated NSCLC who had tried a median ... The median duration of response was 7.1 months and 9.9 months, respectively, based on the separate types of review.

on which patients have logged a median 36.7 months of survival. With the latest overall survival win in hand, J&J believes it holds the key to ending Tagrisso’s long reign in first-line EGFR ...

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 trial data showed.